MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MACROGENICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.33+0.08 (+2.46%)
Close on Oct 19, 2026
- Market cap
- $211.77M
- P/E (TTM)
- –
- Dividend yield
- –
MACROGENICS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative and other agreements | $99.33M | $79.40M | $87.18M | $79.90M | $128.30M | $124.91M | $119.92M | $111.70M | $11.19M | $15.05M | $30.55M | $83.28M | 59.2% | -22.6% |
| Revenue from government agreements | – | – | – | – | – | – | – | – | $1.66M | $1.63M | $1.56M | $1.56M | – | – |
| Product sales, net | – | – | $0 | $2.16M | $6.32M | $11.57M | $16.43M | $18.96M | $19.50M | $19.31M | $17.94M | $17.35M | – | – |
| Contract manufacturing | – | $60.54M | $52.63M | $44.67M | $29.41M | $16.93M | $13.06M | $9.91M | $9.80M | $8.49M | $9.83M | $18.52M | – | – |
| Royalty revenue | – | – | – | – | – | – | – | – | $268.00K | $170.00K | $431.00K | $432.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Macrogenics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.